Delivery Order SPE2DB20D2104-SPE2DB25FNBUV
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Everolimus 5 mg tablets in quantities of 30 units, with a ceiling value of $19,375.40. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract is set for ultimate completion on July 23, 2025, with performance being executed from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a $3,978.63 delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Everolimus 1 mg tablets in unit dose packaging (60 count). This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of July 31, 2025. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a $26,956.89 delivery order to AmerisourceBergen Drug Corp for 60 tablets of Everolimus 0.5 mg, with an ultimate completion date of September 19, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating the award was made through open competition. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major pharmaceutical...
- The U.S. Defense Department's Medical Supply Chain awarded a $18,147.63 delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Everolimus 10 mg tablets in quantities of 30. The contract was competitively awarded without set-aside restrictions under a firm fixed-price delivery order mechanism, with an ultimate completion date of August 28, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a prime pharmaceutical distributor for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Everolimus 5 mg tablets (30-count packages) with a ceiling value of $44,765.09. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of August 13, 2025. The award is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $39,614.76 to AmerisourceBergen Drug Corp for the supply of Everolimus 10 mg tablets (30-count units). This firm fixed price contract, awarded on June 18, 2025, with an ultimate completion date of June 20, 2025, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Everolimus 10 mg tablets (quantity: 30 count) under a firm fixed price contract valued at $18,147.63, with an ultimate completion date of September 19, 2025. This non-set-aside competitive award represents a single delivery order fulfilling federal pharmaceutical procurement needs for military and veteran healthcare systems. The vendor, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Everolimus 10 mg tablets in unit dose packaging (28 count). This is a firm fixed-price delivery order with a ceiling value of $1,358.26 and an ultimate completion date of September 25, 2025. The contract carries no set-aside designation, indicating it was competitively awarded. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,193.76 to AmerisourceBergen Drug Corp for the supply of Everolimus 5 mg tablets in quantities of 30 units. This non-set-aside, competitively awarded contract utilizes firm fixed-price pricing and is scheduled for completion by June 2, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 27, 2025, for the supply of Everolimus 0.25 mg tablets (60-count unit) with a ceiling value of $10,068.17. This firm fixed-price delivery order, which is not set-aside and was competitively awarded, is scheduled for completion by August 28, 2025. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB25FNBUVDelivery Order
The Defense Logistics Agency awarded a $3,977.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 60 tablets of Everolimus 0.75 mg, with a completion deadline of September 30, 2025. This non-set-aside contract was competitively awarded and performed at the contractor's Conshohocken, Pennsylvania location. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of medications and medical supplies to military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, holds a significant position as a critical vendor within the federal medical procurement supply chain. The company's extensive federal contract portfolio with DLA demonstrates its capability to fulfill diverse pharmaceutical requirements across multiple therapeutic domains, including specialty medications, brand-name and generic drugs, and medical supplies. This particular delivery order for Everolimus—a medication used in immunosuppressive and oncological applications—reflects the contractor's ongoing role in supporting Defense Health Agency and other federal healthcare systems through the established prime vendor framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 9/29/25 |